Skip to main content
NAMS logo

NewAmsterdam Pharma Company N.V. (NAMS) Stock: Price, Forecast & Analyst Target

NewAmsterdam Pharma Company N.V. (NAMS) — MoonshotScore 24/100 (Weak band), calculated Nov 18, 2026. Price $19.51 (-1.17%), as of the Nov 19, 2026 trading session; market cap $2.34B.

Educational signal · not a buy or sell recommendation · How to read this

$19.51 −$0.23 (-1.17%) Market Cap $2.34B

NewAmsterdam Pharma Company N.V. · NAMS · NASDAQ

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on metabolic diseases. Their lead candidate, obicetrapib, targets CETP to improve cholesterol levels.

Price as of Nov 19, 2026

Key Statistics

24 of 100

MoonshotScore v2 · NewAmsterdam Pharma Company (NAMS)

Weak
Business Quality Thin (21)
Financial Safety Fortress (87)
Valuation Full (42)
Growth Durability Shrinking (17)
Momentum Slipping (36)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, but bottom-tier quality, stalling growth and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Slipping.

  • quarterly revenue $19M (Q3 FY2026, quarter ended Sep 2026)
  • EPS beat 3 of the last 8 reports
  • Altman Z 22.61 · Piotroski F 1

Holding back: weak fundamentals, soft growth

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for NAMS (52 recorded, newest six shown)
RecordedScoreBand
24Weak
24Weak
24Weak
24Weak
24Weak
24Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$19.51
Change on the day-1.17%
52-week range$17.90 – $42.21
Market capitalisation$2.34B—
Shares traded on the day1.98M

Price & events

Other perspectives

Council score for NewAmsterdam Pharma Company (NAMS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Strong
Valuation Neutral
Growth Durability Negative
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 16, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is NewAmsterdam Pharma Company (NAMS), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. NewAmsterdam Pharma Company N.V. (NAMS) is listed on NASDAQ. It employs 100 people and is led by Michael Harvey Davidson Facp.. In Q3 FY2026 it reported revenue of $19M and net income of -$17M. The market values it at $2.34B.

2 · Latest results

What do the latest results show for NewAmsterdam Pharma Company (NAMS)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $19M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$19M-$17M-$0.14 (diluted)
Q2 FY2026$4M-$64M-$0.52 (diluted)
Q1 FY2026$3M-$48M-$0.40 (diluted)
Q4 FY2025$32,000-$75M-$0.65 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for NewAmsterdam Pharma Company (NAMS)?

Short answer · as of

The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 22.61 · Piotroski F 1. Trailing ratios: ROE -31.4% · ROA -29.8% · current ratio 11.76 · earnings yield -8.2% · free-cash-flow yield -6.2%.

Data-derived red flags

  • Negative return on equity (-31.4%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at NewAmsterdam Pharma Company (NAMS)?

Short answer · as of

Current published price targets run low $45.00 · high $61.00 · consensus $53.75 · median $54.50 against a quoted price of $19.51 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does NewAmsterdam Pharma Company compare with its peers?

Short answer

NewAmsterdam Pharma Company's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eton Pharmaceuticals, Inc. (ETON) Same industry, near in market value$61.99 Nov 18, 2026$1.79B98 5-pillar Nov 18, 2026
Aurinia Pharmaceuticals Inc. (AUPH) Same industry, near in market value$15.13 Nov 18, 2026$2.03B97 5-pillar Nov 18, 2026
ADMA Biologics, Inc. (ADMA) Same industry, near in market value$13.56 Nov 18, 2026$3.01B97 5-pillar Nov 18, 2026
Harmony Biosciences Holdings, Inc. (HRMY) Same industry, near in market value$33.11 Nov 18, 2026$1.94B96 5-pillar Nov 18, 2026
Vericel Corporation (VCEL) Same industry, near in market value$58.26 Nov 19, 2026$2.97B95 5-pillar Nov 18, 2026
Veracyte, Inc. (VCYT) Same industry, near in market value$25.57 Nov 18, 2026$2.06B89 5-pillar Nov 18, 2026
ACADIA Pharmaceuticals Inc. (ACAD) Same industry, near in market value$17.83 Nov 18, 2026$3.08B68 5-pillar Nov 18, 2026
Trevi Therapeutics, Inc. (TRVI) Same industry, near in market value$13.72 Nov 19, 2026$1.96B63 5-pillar Nov 18, 2026
SELLAS Life Sciences Group, Inc. (SLS) Same industry, near in market value$14.86 Nov 19, 2026$3.03B63 5-pillar Nov 18, 2026
MBX Biosciences (MBX) Same industry, near in market value$53.41 Nov 19, 2026$2.65B61 5-pillar Nov 18, 2026
Praxis Precision Medicines, Inc. (PRAX) Named competitor$310.90 Nov 19, 2026$8.69B60 5-pillar Nov 18, 2026
CG Oncology Inc (CGON) Named competitor$81.90 Nov 19, 2026$7.32B26 5-pillar Nov 18, 2026
NewAmsterdam Pharma Company (NAMS) — this page$19.51$2.34B24

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$45.00 – $61.00
Consensus target
$53.75
Median target
$54.50

Consensus record · Captured .

Measured against a quoted price of $19.51 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 30, 2026

Transactions
28
Identified insiders
5
Purchases
1
Sales
9
Other transactions
18

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NAMS in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Duquesne Family OfficeStanley DruckenmillerQ3 20261.83%$81.65MAdded +9.3% shares
Viking GlobalAndreas HalvorsenQ3 20260.18%$59.92MTrimmed −41.4% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about NewAmsterdam Pharma Company (NAMS)?

Read these with our analysis →

What Investors Ask About NewAmsterdam Pharma Company (NAMS)

These answers are editorial: 1 of these 9 answers is drawn from the NAMS research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for NAMS?

NAMS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on metabolic diseases.

Is NAMS a good stock to buy?

Stock Expert AI does not rate NAMS buy, sell or hold. NewAmsterdam Pharma Company N.V. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the NAMS stock price today?

The last price recorded for NewAmsterdam Pharma Company N.V. (NAMS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the NAMS price target?

The analyst consensus price target for NewAmsterdam Pharma Company N.V. (NAMS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What revenue streams does NewAmsterdam Pharma Company N.V. have in healthcare?

As a clinical-stage biopharmaceutical company, NewAmsterdam Pharma Company N.V. currently does not have established revenue streams from marketed products. Its primary focus is on the development of obicetrapib.

What are the key factors to evaluate for NAMS?

NewAmsterdam Pharma Company N.V. (NAMS) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Lead candidate obicetrapib targets CETP, reducing LDL-C and increasing HDL-C, offering a novel approach to cholesterol management. Not financial advice.

How frequently does NAMS data refresh on this page?

NAMS's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven NAMS's recent stock price performance?

NewAmsterdam Pharma Company N.V. (NAMS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel CETP inhibitor mechanism of action. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider NAMS overvalued or undervalued right now?

NewAmsterdam Pharma Company N.V. (NAMS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 12 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.